Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy
NCT Number:
NCT03547973
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Bladder
Study Objectives:
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy in participants with metastatic urothelial cancer (mUC).
Study Documents
(MUSC NetID required for document access)